
    
      Screening procedures will occur up to 42 days. Eligible subjects will randomized at the
      clinic on Day 1 and receive the first dose of study drug. Dosing for 28 days thereafter
      off-site and a total of 5 clinic visits over the treatment period for safety and lab
      assessments. Then a 7 day post-treatment completion follow-up visit (Day 35) and End of Study
      for last safety assessments (Day 49).
    
  